Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $900.00 by Analysts at Wells Fargo & Company

Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) had its target price cut by Wells Fargo & Company from $1,050.00 to $900.00 in a research note issued to investors on Friday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company's stock.

A number of other brokerages have also commented on REGN. Sanford C. Bernstein decreased their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday. Evercore ISI decreased their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Royal Bank of Canada dropped their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research report on Thursday, October 24th. Finally, Bank of America reaffirmed an "underperform" rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,037.33.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $36.71 during trading hours on Friday, hitting $696.88. 1,117,222 shares of the company were exchanged, compared to its average volume of 755,959. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $76.58 billion, a PE ratio of 17.25, a PEG ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals has a one year low of $691.00 and a one year high of $1,211.20. The firm has a fifty day simple moving average of $754.37 and a 200-day simple moving average of $965.13.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Fairfield Financial Advisors LTD bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $37,000. Ashton Thomas Private Wealth LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $39,000. Finally, Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $39,000. Institutional investors own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.